PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab

We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor exhibited extensive infiltration by CD8(+) cytotoxic T lymphocytes, low-to-moderate mutational burden, no PD-L1 staining by commercially availa...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Saby, Papanicolau-Sengos, Antonios, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary, Pabla, Sarabjot, Glenn, Sean T., Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Galluzzi, Lorenzo, Morrison, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279415/
https://www.ncbi.nlm.nih.gov/pubmed/30524881
http://dx.doi.org/10.1080/2162402X.2018.1460298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279415/
https://www.ncbi.nlm.nih.gov/pubmed/30524881
http://dx.doi.org/10.1080/2162402X.2018.1460298

Ejemplares similares